CAR T Referral Process: Challenges Seen and How They Can Be Addressed
Panelists discuss how managing challenges in the chimeric antigen receptor (CAR) T referral process requires addressing key barriers like timely patient identification, insurance authorization delays, and manufacturing coordination while emphasizing the importance of early referrals from community physicians.
EP: 1.Highlighted Data Review of CAR-T in Early R/R MM
EP: 2.Expert Insights: Distinguishing between CARTITUDE-4 vs. KarMMa-3 Trials
EP: 3.CAR-T in R/R MM: Patient Selection & Treatment Sequencing
EP: 4.CAR-T in Earlier Lines of MM Treatment: Patient Eligibility - Considerations between Ide-cel vs. Cilta-cel
EP: 5.MSKCC Insights: CAR T Referral Process
EP: 6.Overview of the CAR T-Cell Therapy Process: Apheresis, Manufacturing, Potential Bridging Therapies, Lymphodepletion, and Infusion
EP: 7.Collaboration With Community Colleagues: Comanagement and Transitions of Care
EP: 8.CAR T Referral Process: Challenges Seen and How They Can Be Addressed
EP: 9.MSKCC Experiences: Successful CAR T Collaborations With Community and International Providers
EP: 10.CAR-T Clinical Trials: Potentially Moving CAR T Into Earlier Lines of MM Treatment
EP: 11.Applying Evidence to Clinical Practice: 63-Year-Old Patient With R/R MM Post Dara-VRd Induction Scenario
EP: 12.CAR T in R/R MM: Key Takeaways and Pearls
Video content above is prompted by the following:
- What are the most common challenges you have encountered in the CAR T referral process, and how have you addressed them at your institution?
- Dr. Usmani to ask Dr. Rajeeve: What advice would you provide to community physicians regarding the appropriate timing and preparation for referring patients for CAR T therapy?
Recap: Recent Advances in the Treatment of Metastatic Castration-Sensitive Prostate Cancer
September 18th 2022Expert oncologists review key studies in the metastatic castration-resistant prostate cancer treatment landscape and discuss how evidence can be applied to clinical practice to improve patient outcomes.
Recap: Updates in Treatment of HER2-Positive Breast Cancer and Brain Metastases
July 16th 2022Sara A. Hurvitz, MD; Stefania Maraka, MD; and Ruta Rao, MD, discuss the evolving landscape of metastatic HER2+ breast cancer, highlighting recent clinical trials and the management of patients with brain metastases.
Recap: Emory Experts Review Treatment Strategies for Transplant-Ineligible Multiple Myeloma
June 20th 2022A panel of experts from Emory University review several key data updates in multiple myeloma from recent meetings and discuss how the data can be applied to clinical practice to improve patient outcomes.
